Clinical Edge Journal Scan

Withdrawal of low-dose prednisolone after long-term administration is feasible in elderly patients with RA


 

Key clinical point: The tapering of low-dose prednisolone over a 3-month schedule led to a moderate increase in disease activity to the levels of the placebo group, suggesting the feasibility of withdrawal of low-dose prednisolone in elderly patients with rheumatoid arthritis (RA) after successful completion of 2 years of therapy.

Major finding: After 3 months of tapering, increase in the Disease Activity Score for 28 Joints was moderate and not significantly different for the prednisolone and placebo groups (between-group difference 0.16; P = .12), with flares being only numerically higher in the prednisolone vs placebo group (45% vs 33%; P = .12).

Study details: This observational controlled cohort study included 191 patients with RA age ≥ 65 years from the GLORIA trial who underwent linear tapering of 5 mg/day prednisolone or placebo after 2 years of administration, to zero over a period of 3 months.

Disclosures: This study was funded by the European Union’s Horizon 2020 research and innovation program. Several authors declared ties with various sources.

Source: Almayali AAH et al. Three-month tapering and discontinuation of long-term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: Placebo-controlled double blind tapering after the GLORIA trial. Ann Rheum Dis. 2023 (Aug 4). doi: 10.1136/ard-2023-223977

Recommended Reading

Meta-analysis identifies factors associated with increased risk for interstitial lung disease in RA
MDedge Rheumatology
Transcutaneous vagus nerve stimulation on the ear proves ineffective in RA treatment
MDedge Rheumatology
Could risk stratifying methotrexate users lead to less frequent testing?
MDedge Rheumatology
Commentary: Comparing DMARD Therapies in RA, August 2023
MDedge Rheumatology
Rheumatoid arthritis may raise risk for aortic stenosis
MDedge Rheumatology
Tools may predict inflammatory arthritis in at-risk patients
MDedge Rheumatology
Low-dose steroids may not increase cardiovascular risk in rheumatoid arthritis
MDedge Rheumatology
Study finds possible link between rheumatoid arthritis and aortic stenosis
MDedge Rheumatology
Antidrug antibodies and response to biologics in RA: Is there a link?
MDedge Rheumatology
Glucocorticoids spike cardiovascular risk in a dose-dependent manner in RA
MDedge Rheumatology